Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report

被引:1
作者
Al-Zoairy, R. [1 ]
Viveiros, A. [1 ]
Zoller, H. [1 ]
Schneeberger, S. [2 ]
Oberhuber, G. [3 ]
Gunsilius, E. [4 ]
Tilg, H. [1 ]
Wolf, D. [4 ]
Rudzki, J. D. [4 ]
机构
[1] Med Univ Innsbruck, Dept Internal Med Gastroenterol Hepatol Endocrino, Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Visceral Transplant & Thorac Surg, Innsbruck, Austria
[3] Pathol Serv Med Univ Innsbruck, INNPATH, Innsbruck, Austria
[4] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol, Innsbruck, Austria
关键词
AL amyloidosis; Multiple myeloma; Transplantation; Case report; AL-AMYLOIDOSIS; DEXAMETHASONE; LENALIDOMIDE; BORTEZOMIB; FEATURES; COMBINATION; CARFILZOMIB;
D O I
10.1186/s13256-020-02511-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The involvement of vital organs in multiple myeloma (MM) with systemic amyloid light-chain (AL) amyloidosis can lead to acute organ failure. In this case, the fear of recurrence or progression of multiple myeloma often excludes those patients from undergoing organ transplantation. Nevertheless, clinically fit patients might benefit from a different therapeutic approach. This case presentation might highlight this particular unmet need and strengthen a different treatment approach. Case presentation To our knowledge, we present the first case of successful simultaneous liver and kidney transplantation, followed by autologous stem cell transplantation in a 60-year-old Caucasian male patient suffering from MM (Durie-Salmon stage IIB; ISS-stage: III, RISS stage: III) with primary AL amyloidosis. Chemotherapy treatment led to end-stage kidney disease requiring dialysis. Liver failure also occurred after at least three cycles of CyBorD (bortezomib, cyclophosphamide, and dexamethasone) of induction therapy with a good hematologic response. Over three years after the initial diagnosis, the patient is reportedly showing an excellent quality of life and a complete remission. Discussion and Conclusion We conclude that kidney and liver transplantation followed by autologous stem cell transplantation can be a treatment option for a selected group of patients with MM if AL amyloidosis is leading. In the end, the remission assessment by IMWG response criteria displayed a complete remission of MM together with complete reconstitution of organ functions (liver & renal function) as long as upfront clinical evaluation excludes significant cardiac involvement and other severe co-morbidities.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis
    Gerardo Rodriguez-Lobato, Luis
    Fernandez de larrea, Carlos
    Teresa Cibeira, M.
    Tovar, Natalia
    Arostegui, Juan I.
    Rosinol, Laura
    Diaz, Tania
    Lozano, Ester
    Elena, Montserrat
    Yaguee, Jordi
    Blade, Joan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (08) : 1269 - 1275
  • [22] Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea
    Kim, Seok Jin
    Lee, Ga Yeon
    Jang, Hye Ryoun
    Choi, Jin-Oh
    Kim, Jung Sun
    Kim, Hee-Jin
    Lee, Soo-Youn
    Min, Ju-Hong
    Jeon, Eun-Seok
    Kim, Kihyun
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2013, 20 (04): : 204 - 211
  • [23] Role of autologous stem-cell transplantation in multiple myeloma
    Attal, Michel
    Harousseau, Jean-Luc
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) : 747 - 759
  • [24] Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation
    Afrough, Aimaz
    Saliba, Rima M.
    Hamdi, Amir
    Honhar, Medhavi
    Varma, Ankur
    Cornelison, A. Megan
    Rondon, Gabriela
    Parmar, Simrit
    Shah, Nina D.
    Bashir, Qaiser
    Hosing, Chitra
    Popat, Uday
    Weber, Donna M.
    Thomas, Sheeba
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (11) : 2197 - 2203
  • [25] Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma
    Chu, Tan-Huy
    Jung, Sung-Hoon
    Kim, Kihyun
    Lee, Jae Hoon
    Mun, Yeung-Chul
    Bang, Soo-Mee
    Yoon, Dok Hyun
    Lee, Ho Sup
    Min, Chang-Ki
    Lee, Je-Jung
    ANNALS OF HEMATOLOGY, 2022, 101 (06) : 1217 - 1226
  • [26] Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency
    Cordes, Stefan
    Gertz, Morie A.
    Buadi, Francis K.
    Lin, Yi
    Lacy, Martha Q.
    Kapoor, Prashant
    Kumar, Shaji K.
    McCurdy, Arleigh
    Dispenzieri, Angela
    Dingli, David
    Hayman, Suzanne R.
    Hogan, William J.
    Pruthi, Rajiv K.
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (01) : 101 - 108
  • [27] Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation
    Abdallah, Maya
    Sanchorawala, Vaishali
    AMERICAN JOURNAL OF MEDICINE, 2022, 135 : S30 - S37
  • [28] The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs
    Wan, Xixi
    Yu, Tian
    Yu, Tao
    Cai, Huili
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [29] Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation
    Zhang, Yuanyuan
    Guo, Jinzhou
    Chen, Wencui
    Zhao, Liang
    Huang, Xianghua
    BONE MARROW TRANSPLANTATION, 2024, 59 (03) : 350 - 358
  • [30] Successful autologous stem cell transplantation for light chain proximal tubulopathy with severe kidney injury
    Kono, Asuka
    Bando, Kana
    Takahata, Atsushi
    Toyota, Shigeo
    CLINICAL CASE REPORTS, 2023, 11 (12):